Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.69 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.69 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138812 | 0.88 | KCNH2 (0.76) | LTA4HHRH3KCNH2MCHR1 | |
| SCHEMBL8773752 | 0.88 | SLC6A3 (0.67) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL5174028 | 0.87 | SLC6A3 (0.65) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7135467 | 0.86 | PSMB1 (0.82) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7140970 | 0.84 | LTA4H (1.00) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7138797 | 0.84 | LTA4H (1.00) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7141103 | 0.83 | LTA4H (1.00) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7133844 | 0.83 | LTA4H (1.00) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL7132044 | 0.83 | LTA4H (1.00) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL5864113 | 0.83 | LTA4H (0.73) | LTA4HHRH3KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |